Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma

Eur J Gastroenterol Hepatol. 2013 Aug;25(8):1001-2. doi: 10.1097/MEG.0b013e32835f1837.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Anticoagulants / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Carcinoma, Hepatocellular / complications
  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / drug therapy*
  • Enoxaparin / therapeutic use
  • Heart Diseases / chemically induced*
  • Heart Diseases / diagnostic imaging
  • Heart Diseases / drug therapy
  • Humans
  • Liver Neoplasms / complications
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / drug therapy*
  • Male
  • Niacinamide / adverse effects
  • Niacinamide / analogs & derivatives*
  • Phenylurea Compounds / adverse effects*
  • Predictive Value of Tests
  • Protein Kinase Inhibitors / adverse effects*
  • Risk Factors
  • Sorafenib
  • Thrombosis / chemically induced*
  • Thrombosis / diagnostic imaging
  • Thrombosis / drug therapy
  • Treatment Outcome
  • Ultrasonography
  • Ventricular Dysfunction / complications

Substances

  • Anticoagulants
  • Antineoplastic Agents
  • Enoxaparin
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Niacinamide
  • Sorafenib